Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALOX15 | P16050 | 6/20 | 0.54 |
| ▸ | SMYD3 | Q9H7B4 | 2/20 | 0.54 |
| ▸ | PBK | Q96KB5 | 2/20 | 0.51 |
| ▸ | F10 | P00742 | 2/20 | 0.48 |
| ▸ | MLLT1 | Q03111 | 1/20 | 0.48 |
| ▸ | CDK2AP1 | O14519 | 2/20 | 0.48 |
| ▸ | CHEK1 | O14757 | 2/20 | 0.48 |
| ▸ | PYGL | P06737 | 1/20 | 0.47 |
| ▸ | PYGM | P11217 | 1/20 | 0.47 |
| ▸ | MDM2 | Q00987 | 1/20 | 0.46 |
| ▸ | PARP1 | P09874 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3605105 | 1.00 | ALOX15 (0.54) | ALOX15SMYD3PBKF10MLLT1 | |
| SCHEMBL3603019 | 0.93 | ALOX15 (0.56) | ALOX15SMYD3F10MLLT1PYGL | |
| SCHEMBL3603913 | 0.93 | ALOX15 (0.56) | ALOX15SMYD3F10MLLT1PYGL | |
| SCHEMBL3603024 | 0.93 | ALOX15 (0.56) | ALOX15SMYD3F10MLLT1PYGL | |
| SCHEMBL3612493 | 0.86 | DRD4 (0.50) | PBKMLLT1PARP1 | |
| SCHEMBL3612490 | 0.86 | DRD4 (0.50) | PBKMLLT1PARP1 | |
| Trifluoroacetic Acid SCHEMBL3610457 | 0.86 | SMYD3 (0.49) | ALOX15SMYD3F10MLLT1PYGL | |
| Trifluoroacetic Acid SCHEMBL3610931 | 0.86 | SMYD3 (0.49) | ALOX15SMYD3F10MLLT1PYGL | |
| SCHEMBL3320273 | 0.84 | MLLT1 (0.54) | MLLT1PYGLPYGMPARP1 | |
| SCHEMBL3320269 | 0.84 | MLLT1 (0.54) | MLLT1PYGLPYGMPARP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100035862-A1 | NOVEL AZA-CYCLIC INDOLE-2-CARBOXAMIDES AND METHODS OF USE THEREOF | ABBOTT LABORATORIES (US) | 2010-02-11 | — | — | US | claimed |
| US-20100035862-A1 | NOVEL AZA-CYCLIC INDOLE-2-CARBOXAMIDES AND METHODS OF USE THEREOF | ABBOTT LABORATORIES (US) | 2010-02-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100035862-A1 | NOVEL AZA-CYCLIC INDOLE-2-CARBOXAMIDES AND METHODS OF USE THEREOF | IDO2, IDO1, INMT | ALOX15 1315/4885SMYD3 811/4885PBK 2463/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.